BMO Capital Maintains Market Perform on Neurocrine Biosciences, Lowers Price Target to $150
Benzinga Newsdesk 2 weeks ago
Analyst RatingsNewsPrice Target
BMO Capital analyst Evan Seigerman maintains Neurocrine Biosciences (NASDAQ:NBIX) with a Market Perform and lowers the price target from $164 to $150.
BMO Capital analyst Evan Seigerman maintains Neurocrine Biosciences (NASDAQ:NBIX) with a Market Perform and lowers the price target from $164 to $150.